Description
Detection of mutations in EGFR, KRAS, BRAF, and HER2 genes is recommended for all patients with locally advanced and metastatic non-small cell lung cancer to determine indications for targeted therapy.
Period of execution
Within 12 days. The specified time does not include the day of biomaterial collection
Biomaterial type
- Tissue sample
- Tissue sample in paraffin block